Molecular pharmacology of multitarget cyclin-dependent kinase inhibitors in human colorectal carcinoma cells

References

• Colorectal cancer: global drug forecast and market analysis to 2028. April 2020. https://store.globaldata.com/report/gdhc182pidr–colorectal-cancer-global-drug-forecast-and-market-analysis-to-2028/ (accessed on Dec 25, 2020).
   Google Scholar
• Wils J. Adjuvant treatment of colon cancer – past, present and future. Arch Oncol. 2006;14:11–15.
   Google Scholar
• Zhang HH, Walker F, Kiflemariam S, et al. Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf. Int J Cancer. 2009;125:297–307.
   PubMed Web of Science ®Google Scholar
• Wang J, Kuropatwinski K, Hauser J, et al. Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis. Mol Cancer Ther. 2007;6:1143–1150.
   PubMed Web of Science ®Google Scholar
• Wang Q, Shi YL, Zhou K, et al. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death Dis. 2018;9(7):739. DOI:10.1038/s41419-018-0776-6
   PubMed Web of Science ®Google Scholar
• Russo P, Malacarne D, Falugi C, et al. RPR-115135, a farnesyl transferase inhibitor, increases 5-FU- cytotoxicity in ten human colon cancer cell lines: role of p53. Int J Cancer. 2002;100:266–275.
   PubMed Web of Science ®Google Scholar
• Porru M, Pompili L, Caruso C, et al. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. J Exp Clin Cancer Res. 2018;37(1):57. DOI:10.1186/s13046-018-0719-1
   PubMedGoogle Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954.
   PubMed Web of Science ®Google Scholar
• Firestein R, Bass AJ, Kim SY, et al. CDK8 is a colorectal cancer oncogene that regulates β-catenin activity. Nature. 2008;455:547–551.
   PubMed Web of Science ®Google Scholar
• Weber MM, Fottner C, Liu SB, et al. Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer. 2002;95:2086–2095.
   PubMed Web of Science ®Google Scholar
• Vigneri PG, Tirrò E, Pennisi MS, et al. The insulin/IGF system in colorectal cancer development and resistance to therapy. Front Oncol. 2015;5:230.
   PubMed Web of Science ®Google Scholar
• Troiani T, Lockerbie O, Morrow M, et al. Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. Mol Cancer Ther. 2006;5:1883–1894.
   PubMed Web of Science ®Google Scholar
• Pabla B, Bissonnette M, Konda VJ. Colon cancer and the epidermal growth factor receptor: current treatment paradigms, the importance of diet, and the role of chemoprevention. World J Clin Oncol. 2015;6:133–141.
   PubMed Web of Science ®Google Scholar
• Ban JO, Lee HS, Jeong H-S, et al. Thiacremonone augments chemotherapeutic agent–induced growth inhibition in human colon cancer cells through inactivation of nuclear factor-κb. Mol. 2009;7:870–879.
   Google Scholar
• Slattery ML, Mullany LE, Sakoda L, et al. The NF-κB signalling pathway in colorectal cancer: associations between dysregulated gene and miRNA expression. J Cancer Res Clin Oncol. 2018;144:269–283.
   PubMed Web of Science ®Google Scholar
• Corvinus FM, Orth C, Moriggl R, et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia. 2005;7:545–555.
   PubMed Web of Science ®Google Scholar
• Watson AJM. Apoptosis and colorectal cancer. Gut. 2004;53:1701–1709.
   PubMed Web of Science ®Google Scholar
• Hector S, Prehn JHM. Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: a review. Biochim Biophys Acta. 2009;1795:117–129.
   PubMed Web of Science ®Google Scholar
• Lee S-Y, Oh SC. Advances of targeted therapy in treatment of unresectable metastatic colorectal cancer. BioMed Research International. 2011;2016:7590245.
   Google Scholar
• Manohar SM, Joshi KS. Promising anticancer activity of multitarget cyclin dependent kinase inhibitors against human colorectal carcinoma cells. Curr Mol Pharmacol. 2022;15:1024–1033.
   PubMed Web of Science ®Google Scholar
• Hahntow IN, Schneller F, Oelsner M, et al. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia. 2004;18:747–755.
   PubMed Web of Science ®Google Scholar
• Dey A, Wong ET, Cheok CF, et al. R-Roscovitine simultaneously targets both the p53 and NF−κB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ. 2008;15:263–273.
   PubMed Web of Science ®Google Scholar
• Meng H, Jin Y, Liu H, et al. SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt. J Hematol Oncol. 2013;6:18.
   PubMed Web of Science ®Google Scholar
• Joshi KS, Rathos MJ, Joshi RD, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276. Mol Cancer Ther. 2007;6:918–925.
   PubMed Web of Science ®Google Scholar
• Joshi KS, Rathos MJ, Mahajan P, et al. P276, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007;6:926–934.
   PubMed Web of Science ®Google Scholar
• Manohar SM, Rathos MJ, Sonawane V, et al. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leuk Res. 2011;35:821–830.
   PubMed Web of Science ®Google Scholar
• Manohar SM, Padgaonkar AA, Jalota-Badhwar A, et al. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells. Prostate Cancer Prostatic Dis. 2012;15:15–27.
   PubMed Web of Science ®Google Scholar
• Manohar SM, Padgaonkar AA, Jalota-Badhwar A, et al. A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells. BMC Cancer. 2011;11:338.
   PubMed Web of Science ®Google Scholar
• Yang B, Eshleman JR, Berger NA, et al. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res. 1996;2:1649–1657.
   PubMed Web of Science ®Google Scholar
• Behrend L, Mohr A, Dick T, et al. Manganese superoxide dismutase induces p53-dependent senescence in colorectal cancer cells. Mol Cell Biol. 2005;25:7758–7769.
   PubMed Web of Science ®Google Scholar
• Macarulla T, Capdevila J, Perez-Garcia J, et al. New approaches and targets in advanced colorectal cancer. Eur J Cancer. 2009;45:79–88.
   PubMedGoogle Scholar
• Buck E, Eyzaguirre A, Brown E, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther. 2006;5:2676–2684.
   PubMed Web of Science ®Google Scholar
• Lin L, Liu A, Peng Z, et al. STAT3 is necessary for proliferation and survival in colon cancer–initiating cells. Cancer Res. 2011;71:1–12.
   Web of Science ®Google Scholar
• Kojima M, Morisaki T, Sasaki N, et al. Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res. 2004;24:675–682.
   PubMed Web of Science ®Google Scholar
• Collet GP, Campbell FC. Overexpression of p65/RelA potentiates curcumin-induced apoptosis in HCT116 human colon cancer cells. Carcinogenesis. 2006;27:1285–1291.
   PubMed Web of Science ®Google Scholar
• Calvani M, Trisciuoglio D, Bergamaschi C, et al. Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res. 2008;68:285–291.
   PubMed Web of Science ®Google Scholar
• Ponce ML. Tube formation: an in vitro matrigel angiogenesis assay. Methods Mol Biol. 2009;467:183–188.
   PubMedGoogle Scholar
• Valster A, Tran NL, Nakada M, et al. Cell migration and invasion assays. Methods. 2005;37:208–215.
   PubMed Web of Science ®Google Scholar
• Gartel AL. Transcriptional inhibitors, p53 and apoptosis. Biochim Biophys Acta. 2008;1786:83–86.
   PubMed Web of Science ®Google Scholar
• Nawroth R, Stellwagen F, Schulz WA, et al. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS ONE. 2011;6(11):e27509. DOI:10.1371/journal.pone.0027509
   PubMed Web of Science ®Google Scholar
• Hsieh W-S, Soo R, Peh B-K, et al. Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clin Cancer Res. 2009;15(4):1435–1442. DOI:10.1158/1078-0432.CCR-08-1748
   PubMed Web of Science ®Google Scholar
• Imai Y, Yamagishi H, Ono Y, et al. Versatile inhibitory effects of the flavonoid-derived PI3K/Akt inhibitor, LY294002, on ATP-binding cassette transporters that characterize stem cells. Clin Transl Med. 2012;1:24.
   PubMed Web of Science ®Google Scholar
• Linford NJ, Yang Y, Cook DG, et al. NeuronaL apoptosis resulting from high doses of the isoflavone genistein: role for calcium and P42/44 mitogen activated protein kinase. J Pharmacol Exp Ther. 2001;299(1):67–75.
   PubMed Web of Science ®Google Scholar
• Tang D, Wu D, Hirao A, et al. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem. 2003;277(15):12710–12717. DOI:10.1074/jbc.M111598200
   Web of Science ®Google Scholar
• Meijer L, Bettayeb K, Galons H. R-roscovitine (CYC-02, Seliciclib). Monographs on enzyme inhibitors. In: Yue E Smith P, editors. Volume 2. CDK inhibitors and their potential as anti-tumor agents. (FL) (FL): CRC Press, Taylor & Francis; 2006. p. 187–226.
   Google Scholar
• Wickenden JA, Jin H, Johnson M, et al. Colorectal cancer cells with the BRAFV600E mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. Oncogene. 2008;27(57):7150–7161. DOI:10.1038/onc.2008.335
   PubMed Web of Science ®Google Scholar
• Dai Y, Yu C, Singh V, et al. Pharmacological Inhibitors of the Mitogen-activated Protein Kinase (MAPK) Kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res. 2001;61:5106–5115.
   PubMed Web of Science ®Google Scholar
• Hahn M, Li W, Yu C, et al. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol Cancer Ther. 2005;4(3):457–470. DOI:10.1158/1535-7163.MCT-04-0137
   PubMed Web of Science ®Google Scholar
• Gwak J, Oh J, Cho M, et al. Galangin suppresses the proliferation of β-catenin response transcription-positive cancer cells by promoting adenomatous polyposis coli/axin/glycogen synthase kinase-3-independent β-catenin degradation. Mol Pharmacol. 2011;79(6):1014–1022. DOI:10.1124/mol.110.069591
   PubMed Web of Science ®Google Scholar
• Müller A, Schmitz M, Tsareva SA, et al. Correlation of malignancy parameters in colorectal carcinoma with up- and downstream signalling partners of STAT3. Poster session presented at: 12th Joint Meeting of the Signal Transduction Society (STS). Signal Transduction: Receptors, Mediators and Genes; 2008 2008 October 29-31; Weimar, Germany.
   Google Scholar
• Du W, Hong J, Wang Y-C, et al. Inhibition of JAK2/STAT3 signaling induces colorectal cancer cell apoptosis via mitochondrial pathway. J Cell Mol Med. 2012;16(8):1878–1888. DOI:10.1111/j.1582-4934.2011.01483.x
   PubMed Web of Science ®Google Scholar
• Krystof V, Baumli S, Fürst R. Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target. Curr Pharm Des. 2012;18:2883–2890.
   PubMed Web of Science ®Google Scholar
• Murono K, Tsuno NH, Kawai K, et al. SN-38 overcomes chemoresistance of colorectal cancer cells induced by hypoxia, through HIF1alpha. Anticancer Res. 2012;32:865–872.
   PubMed Web of Science ®Google Scholar
• Manohar SM. Cyclin-dependent kinases as potential targets for colorectal cancer: past, present and future. Future Med Chem. 2022;14:1087–1105.
   PubMed Web of Science ®Google Scholar
• McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer. 2002;102:463–468.
   PubMed Web of Science ®Google Scholar
• Signore M, Buccarelli M, Pilozzi E, et al. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response. Oncotarget. 2016;7(28):44113–44128. DOI:10.18632/oncotarget.9859
   PubMed Web of Science ®Google Scholar